Baxter International Inc ( (BAX) ) has released its Q3 earnings. Here is a breakdown of the information Baxter International Inc presented to its investors.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Baxter International Inc., a leading global medtech company, specializes in producing diagnostic, critical care, nutrition, kidney care, hospital, and surgical products. The company is renowned for its innovations that save and sustain lives across various healthcare environments. In its third-quarter 2024 earnings report, Baxter International Inc. reported total sales of $3.85 billion, with $2.70 billion from continuing operations. The company’s adjusted diluted earnings per share (EPS) exceeded guidance, reaching $0.80. Despite the challenges posed by Hurricane Helene, Baxter successfully restored production at its North Cove facility, contributing to the positive financial performance. The company’s continuing operations saw a 4% sales increase, driven by strong demand across its Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals segments. Additionally, Baxter’s strategic transformation continues with the pending sale of its Kidney Care segment to Carlyle, expected to close by early 2025. Looking ahead, Baxter remains confident in its growth trajectory, expecting a 1% to 2% sales growth for the full year 2024, despite the hurricane’s impact on North Cove operations. The company anticipates continued operational sales growth and margin improvements following the Kidney Care divestiture.
